Post Meeting 2025

Experts from the ACR’s juvenile idiopathic arthritis (JIA) guideline team, including Susan Shenoi, MBBS, MS, RhMSUS, reviewed key recommendations and changes in response to new therapeutic advances and emerging challenges. The now 15 recommendations for systemic JIA, for example, reflect greater stratification based on clinical…

While honoring rheumatology pioneer Philip Hench, John Stone, MD, MPH, discussed the groundbreaking work that has furthered the understanding and treatment of IgG4-related disease, including the approval of a monoclonal antibody that depletes CD19-positive B cells for use in adults.

During ACR Convergence 2025, representatives from the U.S. Food and Drug Administration detailed the latest approvals of rheumatologic drugs, along with safety updates and considerations for T cell engagers.

Emily C. Gotschlich, MD, gave an overview of several new indications for pediatric rheumatology, including in pediatric psoriatic arthritis, pediatric lupus nephritis, and systemic juvenile idiopathic arthritis. Most approvals leveraged an extrapolation approach, allowing efficacy data from adult populations to support pediatric indications when disease…

Speakers, including Brittany Adler, MD, discussed how postural orthostatic tachycardia syndrome (POTS) and related autonomic disorders have emerged as increasingly prevalent and complex conditions, as well as the role of physical therapy in POTS management.

Better oral health translates into better rheumatic health for patients living with both of these conditions, explained Natalia Trehan, DMD, one of the featured experts in a session on the orofacial complications of systemic sclerosis and Sjögren’s disease.

Autoimmune diseases predominantly affect more females than males, but the underlying significance of some of the immunological differences between the sexes is less clearly defined. Experts, including Petter Brodin, MD, PhD, explored the role of sex hormones in immune responses and autoimmunity.